U.S. General Anesthesia Drugs Market Size to Hit USD 2.56 Billion by 2033

According to Nova One Advisor, the U.S.
general anesthesia drugs market size was valued at USD 1.92 Billion in
2023 and is poised to grow from USD 1.98 Billion in 2024 to USD 2.56 Billion by
2033, at a CAGR of 2.9%% during the forecast period (2024-2033).

The Complete Study is Now Available for Immediate Access
| Download the Sample Pages of this Report@https://www.novaoneadvisor.com/report/sample/8902

U.S. General Anesthesia Drugs Market Key
Takeaways

In 2023, the propofol segment dominated
the market with a substantial share of 25.18% and is also expected to grow
at the fastest CAGR from 2024 of 2033.
The intravenous (IV) segment held the
largest revenue share of 63.15% in 2023 and is also expected to grow at
the fastest CAGR of 3.1% during the forecast period.
The knee and hip replacements segment
dominated the market and captured a substantial revenue share in 2023.
The cancer segment is anticipated to grow
at the fastest CAGR from 2024 to 2033.
The hospitals segment dominated the U.S.
general anesthesia drugs market and accounted for substantial revenue
share of 67.22% in 2023.
Ambulatory surgical centers (ASCs) are
anticipated to achieve the fastest CAGR of 3.6% during the forecast
period.

The market growth is driven by various key factors, such as
increasing shifts in healthcare practices, regulatory updates, rising
technological advancements, and a rising number of surgical procedures. For
instance, in September 2023, the American Society of Aesthetic Plastic Surgeons
reported that there are 26.2 million surgical procedures available in the U.S.

The U.S. general anesthesia drugs market is used during
surgical processes to induce unconsciousness in patients by inhibiting
sympathetic, motor, and sensory nerve transmission at the level of bran that
results in a lack of sensation and unconsciousness and the inability to feel
painful stimuli while controlling involuntary reflexes. The market is primarily
fueled by the increasing volume of surgical processes conducted every year. The
American Society of Anesthesiologists (ASA) attributed this growth to various
factors such as advancements in surgical techniques, increasing prevalence of
chronic diseases, and the rising aging population. Adults aged 65 and older are
highly affected by diseases such as neurological diseases, cancer, diabetes,
COPD, and heart diseases, according to the CDC. In addition, there is
increasing demand for general anesthesia due to the increasing frequency of
elective surgeries, cardiovascular and orthopedic.

Furthermore, the rising healthcare reforms, government
initiatives, and technological innovation in anesthesia are other significant
drivers of U.S. general anesthesia drugs market growth. Recent Developments
such as the development of effective, new, and safer anesthetics delivery and
agent systems. For instance, modern anesthetic drugs provide better control
over anesthesia duration and depth, which accelerates recovery time and patient
safety. In addition, the U.S. government has invested in funding for surgical
procedures and healthcare infrastructure improvements, which indirectly drives
the demand for anesthesia. Moreover, the focus on improving patient safety and
surgical outcomes drives the adoption of advanced anesthesia drugs and
techniques.

Immediate Delivery is Available | Get Full Report
Access@ https://www.novaoneadvisor.com/report/checkout/8902

U.S. General Anesthesia Drugs Market Trends

The increasing research and development activities for
preexisting drug molecules drive market growth.
The increasing number of emergency surgeries and the
prevalence of cancer disease are expected to enhance the market growth.
The increasing advancement in surgeries such as minimally
invasive surgeries and chronic diseases such as lung cancer and
cardiovascular diseases contributed to the growth of the U.S. general
anesthesia drugs market.
The increasing prevalence of dental problems and
increasing number of C-sections during delivery are further anticipated to
drive the market growth.

U.S. General Anesthesia Drugs Market Segment Insights

By drug types

The propofol segment dominated the market share in 2023 and
is expected to grow fastest during the forecast period. The segment growth is
driven by its widespread use of preferred agents for the maintenance and
induction of general anesthesia. Its smooth recovery profile, short duration of
action, and rapid onset make it highly desirable for both complex and profile
procedures. Propofol is supported by extensive clinical data and a
well-established safety profile, which helps maintain its market growth.
Regulatory guidelines and approvals from the U.S. Food and Drug Administration
confirm that propofol remains a safe and reliable option for anesthesia.

Recent developments in propofol formulations, including
enhanced stability and improved delivery systems, have further driven the
market growth. For instance, in August 2024, FDA approval for its Propofol
Injectable Emulsion USP in three single-dose vial concentrations was announced
by Amneal Pharmaceuticals, Inc. This is widely used in hospitals for
maintaining and inducing sedation and anesthesia.

By application types

The knee and hip replacement segment dominated the market
share in 2023. The segment growth is accelerated by factors such as the
increasing prevalence of osteoarthritis and other degenerative joint diseases,
which necessitate surgical interventions including hip and knee replacements.
Over 32.5 million adults in the U.S. are affected by osteoarthritis which
creates a substantial demand for joint replacement surgeries, according to the
Centers for Disease Control and Prevention (CDC). In addition, the aging
population plays an important role in this trend. The frequency of elective
joint replacement surgeries, such as total hip arthroplasties (THAs) and total
knee arthroplasties (TKAs) is rising, due to the rising geriatric population.
These processes often need general anesthesia to facilitate a smooth surgical
process and for effective pain management.

By end-use types

The hospital segment dominated the U.S. general anesthesia
drugs market in 2023. Hospitals are the major settings for complex medical
procedures and major surgeries that need general anesthesia. There are over
6,000 hospitals in the U.S., that handle a vast volume of surgical cases
annually, according to the American Hospital Association (AHA). In addition,
hospitals are tailored with personnel trained and specialized facilities to
maintain the complexities related to general anesthesia. The presence of advanced
monitoring equipment, specialized surgical teams, and anesthesiologists ensures
that patients receive high-quality anesthesia care.

The ambulatory surgical centers segment is expected to grow
fastest during the forecast period. Ambulatory surgical centers offer a
cost-effective additive to traditional hospital-based surgeries, which is a
major factor driving the segment growth. ASCs are designed to provide patients
quicker access to faster recovery times and care and streamline the surgical
process.

Immediate Delivery Available, Get Full Access@ https://www.novaoneadvisor.com/report/checkout/8902

Browse More Insights:

General Anesthesia Drugs Market : The global general anesthesia drugs Market size is expected to be worth around USD 8.58 Billion by 2033 from USD
5.85 Billion in 2023, growing at a Compound Annual Growth Rate (CAGR) of 3.9%
during the forecast period from 2024 to 2033.

U.S. Ambulatory Surgery Center
Market : The U.S. ambulatory surgery center market size was estimated at USD 38.67 billion in 2023 and is projected to
hit around USD 69.91 billion by 2033, growing at a CAGR of 6.1% during the
forecast period from 2024 to 2033.

U.S. Generic Drugs Market : The U.S. generic drugs market size was
valued at USD 133.59 billion in 2023 and is projected to surpass around USD
188.44 billion by 2033, registering a CAGR of 3.5% over the forecast period of
2024 to 2033.

U.S. Pharmaceutical Market : The U.S. pharmaceutical market size was
valued at USD 602.19 billion in 2023 and is projected to surpass around USD
1,093.79 billion by 2033, registering a CAGR of 6.15% over the forecast period
of 2024 to 2033.

Generic Drugs Market : The global generic drugs market size was
estimated at USD 465.19 billion in 2023 and is projected to hit around USD
779.68 billion by 2033, growing at a CAGR of 5.3% during the forecast period
from 2024 to 2033.

Pharmaceutical Market: The global pharmaceutical market size was valued at USD 1,501.90 billion in 2023 and is projected to
surpass around USD 2,717.72 billion by 2033, registering a CAGR of 6.11% over
the forecast period of 2024 to 2033.

Biotechnology Market : The global biotechnology market size was
estimated at USD 1.54 Trillion in 2023 and is projected to hit around USD 5.68
Trillion by 2033, growing at a CAGR of 13.95% during the forecast period from
2024 to 2033.

The U.S. general anesthesia drugs market Company Insights

The U.S. market is dominated by various leading
pharmaceutical companies that combined attributed to significant market growth.
There are different major players in the U.S. such as GE Healthcare, Pfizer,
Hospira Inc., Fresenius SE & Co. KgaA, B. Braun Melsungen AG, AbbVie Inc.,
AstraZeneca, and Baxter International Inc. These major players developed
themselves through extensive research and development activities. They also
expanded their drug portfolios through strategic acquisitions, mergers, and
collaborations.

For instance, in April 2022, the FDA pre-market approval
(PMA) for its End-tidal (Et) Control software for general anesthesia delivery
on its Aisys CS2Anesthesia Delivery System was announced by GE Healthcare. This
company is the only manufacturer approved to provide general anesthesia
delivery with end-tidal concentration control in the United States.

U.S. General Anesthesia Drugs Market Top
Key Companies:

Baxter International Inc.
AstraZeneca
AbbVie Inc.
B. Braun Melsungen AG
Fresenius SE & Co. KgaA
Pfizer
Hospira Inc.
Aspen Pharmacare Holdings Limited
Hikama Pharmaceuticals plc
Abbott Laboratories

The U.S. general anesthesia drugs market Recent
Developments

In February 2024, Fentanyl Citrate Injection, USP,
in the US was launched by Hikma Pharmaceuticals PLC. This medication is
designed for short-duration analgesia during maintenance, induction,
premedication, anesthesia, and immediate postoperative recovery.
In November 2023, Lupin Limited (Lupin), the global
pharmaceutical company announced the release of Rocuronium Bromide
injection in two variations such as 100 mg/10 mL (10 mg/mL) and 50 mg/5 mL
(10 mg/mL) multiple-dose vials. By the United States Food and Drug
Administration, this launch follows the approval of an Abbreviated New
Drug Application (ANDA).

U.S. General Anesthesia Drugs Market
Report Segmentation

This report forecasts revenue growth at
country levels and provides an analysis of the latest industry trends in each
of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc.
has segmented the U.S. General Anesthesia Drugs market.

By Drug

Sevoflurane
Propofol
Dexmedetomidine
Remifentanil
Desflurane
Midazolam
Others – (Sufentanil, Fentanyl, Ketamine,
Isoflurane, Thiopental, etc.)

By Route of Administration

By End-use

Hospitals
Ambulatory Surgical Centers
Others

By Application

Heart Surgeries
Cancer
General Surgery
Knee and hip replacements
Others

Immediate Delivery Available | Buy This Premium Research
https://www.novaoneadvisor.com/report/checkout/8902

Unlock industry potential through
cutting-edge research, data-driven insights, and strategic guidance. We empower
businesses to navigate, innovate, and excel.

USA : +1
804 441 9344

APAC : +61
485 981 310 or +91 87933 22019

Europe : +44
7383 092 044

Email: sales@novaoneadvisor.com

Web: https://www.novaoneadvisor.com/